Cervo Silvia

 

Silvia Cervo

Cervo Silvia

vcanzonieri@cro.it

Title of Presentation

“Biobanks as tools for biomarkers validation in colon cancer”

 

Date and Place

Session D6

 

Speaker Biography

Cervo Silvia, graduated whith honours in Biotechnology in 2006 and subsequently in Molecular Biology at the University of Padua. She holds post-graduate qualifications in “Hygiene and quality systems” and in “Clinical Nutrition”, she is currently resident in Clinical Pathology. She is the Project and Quality Manager of CRO-Biobank at CRO Aviano National Cancer Institute in Italy. Her main expertise is in human biobanking and associated areas, such as informed consent and quality of biological material. She performs researches in the field of oncology, particularly: tumor biomarkers, SERS (Surface Enhanced Raman Spectroscopy).

 

Abstract

Colorectal cancer (CRC) is the third most commonly diagnosed malignant and it is biologically heterogeneous. Molecular characterization, including somatic mutations in BRAF and KRAS, microsatellite instability (MSI), and CpG island methylator phenotype (CIMP), has provided evidence of multiple tumor subtypes. Three main pathways, have been identified: the chromosomal instability (CIN); the MSI; and the CIMP. Availability of definite biomarkers from accessible samples may be an invaluable adjunct to anticipate the diagnosis, improve prognostic information, analyze tumor heterogeneity and establish therapeutic options. New technologies, such as NGS have enabled further characterization by identifying mutated genes, including well-known genes, such as APC, SMAD4, and PIK3CA as well as some that are less known, such as SOX9 or ACVR1B.. In our Pathology Department, more than 700 archived tissue samples of CRC are available. Moreover, CRO-Biobank has collected samples from 400 patients: serum, plasma-ETDA, plasma-citrate, buffy coat, more than 300 fresh tissue samples with more than 100 samples from paired metastases and healthy tissues, along with clinico-pathological parameters. The ongoing analyses have been focused on: the new antibody (VE1) to BRAF V600E for the use in IHC; the Cadherin 17 (CDH17), for CRCs with undifferentiated morphology and BTK; hypoxia-regulated genes, including carbonic anhydrase IX (CAIX); the influence of the stroma on neoplastic growth; CD55 and CD59 that are of clinical relevance for the tumor differentiation and TNM staging; dysregulated MiRNAs, as biomarker of intra-tumor heterogeneity; metastasis associated in colon cancer 1 (MACC1).